get a key
steadybase-$ company AEON
account_id none on file
legal_name AEON Biopharma, Inc.
ticker AEON
cik 1837607
domain aeonbiopharma.com
entry_point_account_id none on file
name AEON Biopharma Inc.
exchange NYSE
sector Health Care
calls 0 filings 11 executives 4 family 0
why_nownone on file
callsnone on file
filings
Other SG&A expenses include travel expenses, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses, and allocated facilities-related expenses.

filing / Aug 12, 2026 / receipt

Additionally, research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses and an allocation of facility overhead expenses.

filing / Aug 12, 2026 / receipt

The decrease in SG&A expenses was primarily attributable to a decrease in professional and legal fees in the second quarter of 2026 compared to the second quarter of 2025, slightly offset by increases in payroll-related expenses including accrued compensation expense in the current year compared to prior year and an increase in headcount in 2026 compared to the prior year.

filing / Aug 12, 2026 / receipt

In July 2026, the Company entered into a non-cancellable lease agreement for new office space located in Aliso Viejo, California.

filing / Aug 12, 2026 / receipt

In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024.

filing / Aug 12, 2026 / receipt

In the second quarter of 2026, the Company entered into a sublease agreement for its existing corporate office space. Under the terms of the sublease, the subtenant is expected to take occupancy in the third quarter of 2026, subject to customary conditions.

filing / Aug 12, 2026 / receipt

Other SG&A expenses include travel expenses, market research and analysis, conferences and trade shows, professional services fees, including legal, audit and tax fees, insurance costs, general corporate expenses, and allocated facilities-related expenses.

filing / May 14, 2026 / receipt

Additionally, research and development expenses include employee compensation, including stock-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses and an allocation of facility overhead expenses.

filing / May 14, 2026 / receipt

On March 6, 2026, the Company’s board of directors appointed John Bencich as the Company’s Chief Financial Officer, effective as of March 9, 2026 and principal financial officer, effective as of April 1, 2026.

filing / May 14, 2026 / receipt

In December 2021, the Company entered into a three-year non-cancellable lease for office space. The lease was extended for an additional five years in March 2024.

filing / May 14, 2026 / receipt

In April 2026, the Company entered into a sublease agreement for its existing corporate office space, which was finalized with landlord consent in May 2026.

filing / May 14, 2026 / receipt

executives
Jennifer Sy Chief Accounting Officer linkedin receipt
John Bencich Chief Financial Officer linkedin receipt
Jost Fischer President & CEO, Board Member - receipt
Robert Bancroft Principal Executive Officer - receipt
familynone on file
upcoming
2026-11-13 earnings call scheduled ir
changes
2026-03-09 Chief Financial Officer, appointed sec_8k
2025-04-21 Interim President and Chief Executive Officer, departed sec_8k
2025-04-21 Principal Executive Officer, appointed sec_8k
2025-04-08 Chief Accounting Officer, appointed sec_8k
2025-04-08 Interim Chief Executive Officer, appointed sec_8k
2025-03-27 Interim CEO, appointed sec_8k
mcp_package_hint
steadybase-$